<code id='C84C949861'></code><style id='C84C949861'></style>
      • <acronym id='C84C949861'></acronym>
      <center id='C84C949861'><center id='C84C949861'><tfoot id='C84C949861'></tfoot></center><abbr id='C84C949861'><dir id='C84C949861'><tfoot id='C84C949861'></tfoot><noframes id='C84C949861'>
      • <optgroup id='C84C949861'><strike id='C84C949861'><sup id='C84C949861'></sup></strike><code id='C84C949861'></code></optgroup>
        5. <b id='C84C949861'><label id='C84C949861'><select id='C84C949861'><dt id='C84C949861'><span id='C84C949861'></span></dt></select></label></b><u id='C84C949861'></u>
          <i id='C84C949861'><strike id='C84C949861'><tt id='C84C949861'><pre id='C84C949861'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / hotspot / Wikipedia      
           
     
           
      
          Wikipedia 
           
      
           
      
           
       2025-09-29 12:03:12 
   
      
           
      
           
                        
          Wikipedia  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：38
                                  
                                    
          
                                   
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP
          A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.
          Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.
          advertisement
          Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
                      
                              
          
                                 Previous article：

                                
                                          Time to name cancers by genetics, not organ of origin, expert says
                                
                            
          Next article：  
                                      
                                          Alkermes shareholders re
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles